肠道菌群在前列腺癌中的研究进展
Research Progress on Gut Microbiota in Prostate Cancer
DOI: 10.12677/acm.2026.163963, PDF,   
作者: 佘秋蕊*, 刘 瑞#：重庆医科大学附属第二医院肿瘤科，重庆
关键词: 肠道菌群；前列腺癌；肿瘤微环境；Gut Microbiota； Prostate Cancer； Tumor Microenvironment
摘要: 近年来，肠道菌群在癌症发生、发展及治疗中的作用逐渐成为研究的前沿领域。本文系统地探讨了肠道菌群与前列腺癌之间的复杂关系，重点分析其在免疫调控、代谢途径及雄激素代谢中的多重机制。肠道菌群失调与慢性炎症的加剧及肿瘤微环境的恶化密切相关，这种失衡可能削弱抗雄激素治疗及免疫检查点抑制剂的疗效。此外，肠道菌群代谢产物(如短链脂肪酸和胆汁酸)通过多条信号通路影响癌细胞的增殖和存活。益生菌、益生元及膳食干预等策略在癌症治疗中的潜在价值逐步显现，为精准医学的发展提供了新的方向。最后，本文呼吁未来研究整合多组学数据，以进一步推动肠道菌群在前列腺癌防治中的应用。
Abstract: In recent years, the role of gut microbiota in the occurrence, development, and treatment of cancer has gradually become a cutting-edge research area. This article systematically explores the complex relationship between gut microbiota and prostate cancer, focusing on its multiple mechanisms in immune regulation, metabolic pathways, and androgen metabolism. Gut microbiota dysbiosis is closely related to the exacerbation of chronic inflammation and the deterioration of the tumor microenvironment; this imbalance may weaken the efficacy of anti-androgen therapy and immune checkpoint inhibitors. Furthermore, gut microbiota metabolites (such as short-chain fatty acids and bile acids) affect the proliferation and survival of cancer cells through multiple signaling pathways. The potential value of strategies such as probiotics, prebiotics, and dietary interventions in cancer treatment is gradually emerging, providing new directions for the development of precision medicine. Finally, this article calls for future research to integrate multi-omics data to further promote the application of gut microbiota in the prevention and treatment of prostate cancer.
文章引用：佘秋蕊, 刘瑞. 肠道菌群在前列腺癌中的研究进展[J]. 临床医学进展, 2026, 16(3): 1770-1777. https://doi.org/10.12677/acm.2026.163963

参考文献

[1] Rawla, P. (2019) Epidemiology of Prostate Cancer. World Journal of Oncology, 10, 63-89. [Google Scholar] [CrossRef] [PubMed]
[2] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[3] Zitvogel, L., Pietrocola, F. and Kroemer, G. (2017) Nutrition, Inflammation and Cancer. Nature Immunology, 18, 843-850. [Google Scholar] [CrossRef] [PubMed]
[4] Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J.A. and Kroemer, G. (2018) The Gut Microbiota Influences Anticancer Immunosurveillance and General Health. Nature Reviews Clinical Oncology, 15, 382-396. [Google Scholar] [CrossRef] [PubMed]
[5] Zhu, Q., Gao, R., Wu, W. and Qin, H. (2013) The Role of Gut Microbiota in the Pathogenesis of Colorectal Cancer. Tumor Biology, 34, 1285-1300. [Google Scholar] [CrossRef] [PubMed]
[6] Kho, Z.Y. and Lal, S.K. (2018) The Human Gut Microbiome—A Potential Controller of Wellness and Disease. Frontiers in Microbiology, 9, Article 1835. [Google Scholar] [CrossRef] [PubMed]
[7] Zmora, N., Suez, J. and Elinav, E. (2018) You Are What You Eat: Diet, Health and the Gut Microbiota. Nature Reviews Gastroenterology & Hepatology, 16, 35-56. [Google Scholar] [CrossRef] [PubMed]
[8] Belkaid, Y. and Hand, T.W. (2014) Role of the Microbiota in Immunity and Inflammation. Cell, 157, 121-141. [Google Scholar] [CrossRef] [PubMed]
[9] Koh, A., De Vadder, F., Kovatcheva-Datchary, P. and Bäckhed, F. (2016) From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell, 165, 1332-1345. [Google Scholar] [CrossRef] [PubMed]
[10] Ridlon, J.M., Kang, D. and Hylemon, P.B. (2006) Bile Salt Biotransformations by Human Intestinal Bacteria. Journal of Lipid Research, 47, 241-259. [Google Scholar] [CrossRef] [PubMed]
[11] De Lazzari, G., Opattova, A. and Arena, S. (2024) Novel Frontiers in Urogenital Cancers: From Molecular Bases to Preclinical Models to Tailor Personalized Treatments in Ovarian and Prostate Cancer Patients. Journal of Experimental & Clinical Cancer Research, 43, Article No. 146. [Google Scholar] [CrossRef] [PubMed]
[12] Fujita, K., Matsushita, M., Banno, E., De Velasco, M.A., Hatano, K., Nonomura, N., et al. (2022) Gut Microbiome and Prostate Cancer. International Journal of Urology, 29, 793-798. [Google Scholar] [CrossRef] [PubMed]
[13] Porter, C.M., Shrestha, E., Peiffer, L.B. and Sfanos, K.S. (2018) The Microbiome in Prostate Inflammation and Prostate Cancer. Prostate Cancer and Prostatic Diseases, 21, 345-354. [Google Scholar] [CrossRef] [PubMed]
[14] Tilg, H. and Moschen, A.R. (2014) Microbiota and Diabetes: An Evolving Relationship. Gut, 63, 1513-1521. [Google Scholar] [CrossRef] [PubMed]
[15] Garrett, W.S. (2015) Cancer and the Microbiota. Science, 348, 80-86. [Google Scholar] [CrossRef] [PubMed]
[16] Tanabe, S. (2013) The Effect of Probiotics and Gut Microbiota on Th17 Cells. International Reviews of Immunology, 32, 511-525. [Google Scholar] [CrossRef] [PubMed]
[17] Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., et al. (2013) Treg Induction by a Rationally Selected Mixture of Clostridia Strains from the Human Microbiota. Nature, 500, 232-236. [Google Scholar] [CrossRef] [PubMed]
[18] Fasano, A. (2020) All Disease Begins in the (Leaky) Gut: Role of Zonulin-Mediated Gut Permeability in the Pathogenesis of Some Chronic Inflammatory Diseases. F1000Research, 9, Article 69. [Google Scholar] [CrossRef] [PubMed]
[19] Starling, S. (2018) Lipid Surveillance by Skin ILCs. Nature Reviews Immunology, 18, 78-78. [Google Scholar] [CrossRef] [PubMed]
[20] Suh, J. and Rabson, A.B. (2003) NF‐κB Activation in Human Prostate Cancer: Important Mediator or Epiphenomenon? Journal of Cellular Biochemistry, 91, 100-117. [Google Scholar] [CrossRef] [PubMed]
[21] Ghandadi, M. and Sahebkar, A. (2016) Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance. Current Pharmaceutical Design, 22, 518-526. [Google Scholar] [CrossRef] [PubMed]
[22] Culig, Z. and Puhr, M. (2012) Interleukin-6: A Multifunctional Targetable Cytokine in Human Prostate Cancer. Molecular and Cellular Endocrinology, 360, 52-58. [Google Scholar] [CrossRef] [PubMed]
[23] Sfanos, K.S., Hempel, H.A. and De Marzo, A.M. (2014) The Role of Inflammation in Prostate Cancer. Advances in Experimental Medicine and Biology, 816, 153-181. [Google Scholar] [CrossRef] [PubMed]
[24] Martin-Orozco, N. and Dong, C. (2009) The IL-17/IL-23 Axis of Inflammation in Cancer: Friend or Foe? Current Opinion in Investigational Drugs, 10, 543-549.
[25] Wang, X., Wong, K., Ouyang, W. and Rutz, S. (2017) Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harbor Perspectives in Biology, 11, a028548. [Google Scholar] [CrossRef] [PubMed]
[26] Shyanti, R.K., Greggs, J., Malik, S. and Mishra, M. (2024) Gut Dysbiosis Impacts the Immune System and Promotes Prostate Cancer. Immunology Letters, 268, Article ID: 106883. [Google Scholar] [CrossRef] [PubMed]
[27] Candela, M. (2014) Inflammation and Colorectal Cancer, When Microbiota-Host Mutualism Breaks. World Journal of Gastroenterology, 20, 908-922. [Google Scholar] [CrossRef] [PubMed]
[28] Yin, Q., Ni, J. and Ying, J. (2024) Potential Mechanisms and Targeting Strategies of the Gut Microbiota in Antitumor Immunity and Immunotherapy. Immunity, Inflammation and Disease, 12, e1263. [Google Scholar] [CrossRef] [PubMed]
[29] Tan, J., McKenzie, C., Potamitis, M., Thorburn, A.N., Mackay, C.R. and Macia, L. (2014) The Role of Short-Chain Fatty Acids in Health and Disease. Advances in Immunology, 121, 91-119. [Google Scholar] [CrossRef] [PubMed]
[30] Di Ciaula, A., Wang, D.Q.-H., Molina-Molina, E., Lunardi Baccetto, R., Calamita, G., Palmieri, V.O., et al. (2017) Bile Acids and Cancer: Direct and Environmental-Dependent Effects. Annals of Hepatology, 16, S87-S105. [Google Scholar] [CrossRef] [PubMed]
[31] Sun, M., Ma, N., He, T., Johnston, L.J. and Ma, X. (2019) Tryptophan (TRP) Modulates Gut Homeostasis via Aryl Hydrocarbon Receptor (AHR). Critical Reviews in Food Science and Nutrition, 60, 1760-1768. [Google Scholar] [CrossRef] [PubMed]
[32] Ozkan, A.D., Eskiler, G.G., Kazan, N. and Turna, O. (2022) Histone Deacetylase Inhibitor Sodium Butyrate Regulates the Activation of Toll-Like Receptor 4/Interferon Regulatory Factor-3 Signaling Pathways in Prostate Cancer Cells. Journal of Cancer Research and Therapeutics, 19, 1812-1817. [Google Scholar] [CrossRef] [PubMed]
[33] Lipska, K., Gumieniczek, A. and Filip, A.A. (2020) Anticonvulsant Valproic Acid and Other Short-Chain Fatty Acids as Novel Anticancer Therapeutics: Possibilities and Challenges. Acta Pharmaceutica, 70, 291-301. [Google Scholar] [CrossRef] [PubMed]
[34] Feitelson, M.A., Arzumanyan, A., Medhat, A. and Spector, I. (2023) Short-Chain Fatty Acids in Cancer Pathogenesis. Cancer and Metastasis Reviews, 42, 677-698. [Google Scholar] [CrossRef] [PubMed]
[35] Zhong, W., Wu, K., Long, Z., Zhou, X., Zhong, C., Wang, S., et al. (2022) Gut Dysbiosis Promotes Prostate Cancer Progression and Docetaxel Resistance via Activating NF-κB-IL6-STAT3 Axis. Microbiome, 10, Article No. 94. [Google Scholar] [CrossRef] [PubMed]
[36] Liu, Y., Zhang, S., Zhou, W., Hu, D., Xu, H. and Ji, G. (2022) Secondary Bile Acids and Tumorigenesis in Colorectal Cancer. Frontiers in Oncology, 12, Article 813745. [Google Scholar] [CrossRef] [PubMed]
[37] Xi, Y., Yani, Z., Jing, M., Yinhang, W., Xiaohui, H., Jing, Z., et al. (2021) Mechanisms of Induction of Tumors by Cholesterol and Potential Therapeutic Prospects. Biomedicine & Pharmacotherapy, 144, Article ID: 112277. [Google Scholar] [CrossRef] [PubMed]
[38] Abu‐Ghazaleh, N., Chua, W.J. and Gopalan, V. (2020) Intestinal Microbiota and Its Association with Colon Cancer and Red/Processed Meat Consumption. Journal of Gastroenterology and Hepatology, 36, 75-88. [Google Scholar] [CrossRef] [PubMed]
[39] Fusco, W., Lorenzo, M.B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., et al. (2023) Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients, 15, Article 2211. [Google Scholar] [CrossRef] [PubMed]
[40] Sidahmed, E., Freedland, S.J., Wang, M., et al. (2024) Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies. Journal of the Academy of Nutrition and Dietetics, 125, 11-23.e22.
[41] Pernigoni, N., Zagato, E., Calcinotto, A., Troiani, M., Mestre, R.P., Calì, B., et al. (2021) Commensal Bacteria Promote Endocrine Resistance in Prostate Cancer through Androgen Biosynthesis. Science, 374, 216-224. [Google Scholar] [CrossRef] [PubMed]
[42] Kunc, M., Gabrych, A. and Witkowski, J.M. (2015) Microbiome Impact on Metabolism and Function of Sex, Thyroid, Growth and Parathyroid Hormones. Acta Biochimica Polonica, 63, 189-201. [Google Scholar] [CrossRef] [PubMed]
[43] Lin, G., Zhang, F., Weng, X., Hong, Z., Ye, D. and Wang, G. (2024) Role of Gut Microbiota in the Pathogenesis of Castration-Resistant Prostate Cancer: A Comprehensive Study Using Sequencing and Animal Models. Oncogene, 43, 2373-2388. [Google Scholar] [CrossRef] [PubMed]
[44] Senchukova, M.A. (2023) Microbiota of the Gastrointestinal Tract: Friend or Foe? World Journal of Gastroenterology, 29, 19-42. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, L. (2023) Changes in the Gut Microbial Profile during Long-Term Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer and Prostatic Diseases, 27, 667-673. [Google Scholar] [CrossRef] [PubMed]
[46] Terrisse, S., Zitvogel, L. and Kroemer, G. (2022) Effects of the Intestinal Microbiota on Prostate Cancer Treatment by Androgen Deprivation Therapy. Microbial Cell, 9, 190-194. [Google Scholar] [CrossRef] [PubMed]
[47] Cao, H., Zhang, D., Wang, P., Wang, Y., Shi, C., Wu, H., et al. (2024) Gut Microbiome: A Novel Preventive and Therapeutic Target for Prostatic Disease. Frontiers in Cellular and Infection Microbiology, 14, Article 1431088. [Google Scholar] [CrossRef] [PubMed]
[48] Zitvogel, L., Ayyoub, M., Routy, B. and Kroemer, G. (2016) Microbiome and Anticancer Immunosurveillance. Cell, 165, 276-287. [Google Scholar] [CrossRef] [PubMed]
[49] Pernigoni, N., Guo, C., Gallagher, L., Yuan, W., Colucci, M., Troiani, M., et al. (2023) The Potential Role of the Microbiota in Prostate Cancer Pathogenesis and Treatment. Nature Reviews Urology, 20, 706-718. [Google Scholar] [CrossRef] [PubMed]
[50] Li, S., Hsu, W., Chang, J. and Shih, C. (2019) Combination of Lactobacillus Acidophilus and Bifidobacterium Animalis Subsp. Lactis Shows a Stronger Anti-Inflammatory Effect than Individual Strains in HT-29 Cells. Nutrients, 11, Article 969. [Google Scholar] [CrossRef] [PubMed]
[51] Touchefeu, Y., Montassier, E., Nieman, K., Gastinne, T., Potel, G., Bruley des Varannes, S., et al. (2014) Systematic Review: The Role of the Gut Microbiota in Chemotherapy‐ or Radiation‐Induced Gastrointestinal Mucositis—Current Evidence and Potential Clinical Applications. Alimentary Pharmacology & Therapeutics, 40, 409-421. [Google Scholar] [CrossRef] [PubMed]
[52] Kure, A., Tsukimi, T., Ishii, C., Aw, W., Obana, N., Nakato, G., et al. (2022) Gut Environment Changes Due to Androgen Deprivation Therapy in Patients with Prostate Cancer. Prostate Cancer and Prostatic Diseases, 26, 323-330. [Google Scholar] [CrossRef] [PubMed]
[53] Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X., Han, T., et al. (2023) Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade. Cancer Research, 83, 3710-3725. [Google Scholar] [CrossRef] [PubMed]
[54] Perets, R., Meshner, S., Tirosh, O., Eshar, S., Metz-Breiner, A., Kruger Ben-Shabat, S., et al. (2024) Preliminary Results from a FIH, Open-Label Phase 1 Study with BMC128, a Rationally Designed Live Bacterial Consortium, in Combination with Nivolumab. Journal of Clinical Oncology, 42, 8631-8631. [Google Scholar] [CrossRef] 
[55] Han, Z. and Ai, J. (2024) Editorial: Biomarkers and Immunotherapy for Genitourinary Tumors. Frontiers in Immunology, 15, Article 1394170. [Google Scholar] [CrossRef] [PubMed]
[56] Baruch, E.N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., et al. (2021) Fecal Microbiota Transplant Promotes Response in Immunotherapy-Refractory Melanoma Patients. Science, 371, 602-609. [Google Scholar] [CrossRef] [PubMed]

为你推荐